Breaking News

US Govt. Invests $143M to Scale Up SiO2’s Primary Packaging Platform

To accelerate capacity scale-up of advanced primary packaging platform for COVID-19 vaccines and therapeutics

By: Contract Pharma

Contract Pharma Staff

SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, has unveiled a $143 million agreement with the federal government. The agreement with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) in partnership with the Biomedical Advanced Research and Development Authority (BARDA), part o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters